海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
2336件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Recruiting
- A Study Investigating the Efficacy, Safety, and PK Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe AD
- Atopic Dermatitis
- Canada, Czechia, Poland, United Kingdom, United States
- 2018-04-27
Recruiting
- Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
- Mild Cognitive Impairment;Alzheimer Disease;Mild Cognitive Impairment;Alzheimer Disease;Mild Cognitive Impairment;Alzheimer Disease
- France, Italy, Spain, Sweden
- 2018-03-02
Not recruiting
- Influence of Routinely Adding Ultrasound Screening in Medical Department
- Heart Disease;Dyspnea;Aortic Disease;Kidney Disease;Liver Disease
- Norway
- 2011-03-30
Recruiting
- Study of LM11A-31-BHS in Mild-moderate AD Patients
- Mild to Moderate Alzheimer's Disease;Mild to Moderate Alzheimer's Disease;Mild to Moderate Alzheimer's Disease
- Austria, Czech Republic, Czechia, Germany, Spain, Sweden
- 2017-02-03
Not recruiting
- Effects of Added D-fagomine on Glycaemic Responses to Sucrose
- Reduction of Post-prandial Glycaemic Response;Reduction of Post-prandial Glycaemic Response;Reduction of Post-prandial Glycaemic Response;Reduction of Post-prandial Glycaemic Response
- United Kingdom
- 2013-03-12
Authorised
- Treatment of neuroendocrine tumours with genetically modified adenovirus
- Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms with varying symptoms, tumor biology and treatment response. NETs may occur in any organ, most commonly they are observed in the gastroenteropancreatic system and lungs. Most NET patients are diagnosed at advanced stage, 65% of them will die within 5 years. The only curative treatment is surgery with complete resection of the primary tumor. However, more than 50% of patients exhibit metastatic disease, where there is no cure. MedDRA version: 18.1 Level: PT Classification code 10071542 Term: Neuroendocrine carcinoma metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Sweden
- 2015-09-27
Not recruiting
- I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD
- Alzheimer Disease;Alzheimer Disease;Alzheimer Disease
- United Kingdom
- 2016-08-17
Not Recruiting
- A Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Prodromal AD (APECS).
- Prodromal Alzheimer's Disease MedDRA version: 20.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Finland, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Poland, Spain, Switzerland, United Kingdom, United States
- 2015-08-27
Not Recruiting
- A 24-week, international, multi centre, randomised, open label, parallel group, phase IV clinical trial investigating changes in bone formation markers in postmenopausal women with primary osteoporosis treated with either PTH(1-84) or strontium ranelate
- Primary postmenopausal osteoporosis MedDRA version: 9.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausal
- Austria, Spain
- 2007-03-07
Not Recruiting
- An open label, international, multi centre, parallel group, phase III b, randomised trial, investigating lumbar spine Bone Mineral Density (BMD) changes in postmenopausal women with primary osteoporosis initially treated with 12 months of full length parathyroid hormone (PTH 1-84) followed by 12 months of treatment with risedronate followed by either 12 months treatment with PTH (1-84) or risedronate. - Sequential treatment of postmenopausal women with primary osteoporosis
- Primary postmenopausal osteoporosis MedDRA version: 9.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausal
- Germany, Greece, Italy, Spain, Sweden, United Kingdom
- 2005-11-22
